Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268175 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT02268175: Completed Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT02268175 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02268175, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This study is comparing the effectiveness of enzalutamide with or without abiraterone acetate for men with high-risk, localized prostate cancer.
Primary Outcome
pCR is defined as the absence of morphologically identifiable carcinoma in the radical prostatectomy (RP) specimen. MRD is defined as the largest cross-sectional dimension of residual tumor measuring \</= 0.5 cm. If the tumor is multifocal, the size of the largest focus will be used to determine the size of the residual tumor.
Interventions
- DRUG Prednisone
- DRUG Enzalutamide
- DRUG Abiraterone Acetate
- DRUG Leuprolide Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2014-10 |
| Est. Completion | 2021-12 |
| Phase | Phase 2 |
What the finished NCT02268175 record still lists
NCT02268175 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT02268175 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02268175 about?
NCT02268175 is a clinical study titled "Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate". This study is comparing the effectiveness of enzalutamide with or without abiraterone acetate for men with high-risk, localized prostate cancer.
What is the current status of trial NCT02268175?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2014-10. Estimated completion is 2021-12.
What interventions are being tested in trial NCT02268175?
The interventions under investigation include: Prednisone (DRUG), Enzalutamide (DRUG), Abiraterone Acetate (DRUG), Leuprolide Acetate (DRUG).
Who is sponsoring clinical trial NCT02268175?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02268175's enrollment target sits among peer trials
75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia